Castle Biosciences CSTL 深 沪
等待开盘 07-19 09:30:00 美东时间
16.53
-0.860
-4.95%
华盛通- 最 高17.7165
- 今 开17.58
- 成交量 26.96万股
- 最 低 16.4125
- 昨 收 17.39
- 总市值 4.77亿
- 52周最高 35.84
- 市盈率 静 26.51
- 换手率 0.93%
- 52周最低 15.45
- 委 比 -58.80%
- 总股本 2887.23万
- 历史最高 107.69
- 量 比 1.07
- 振 幅 7.50%
- 历史最低 9.2601
- 每 手 1
- 风险率 5.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Castle Biosciences, Inc. has been recognized as a national Healthcare Industry Top Workplace, an Arizona Top Workplace, and received five Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values. These employee-driven honors highlight Castle's commitment to fostering a strong, people-first culture and its dedication to innovation and impactful patient care. The award...
07-17 11:00
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
Castle Biosciences Inc. will release its Q2 2025 financial results after market close on August 4, 2025. Management will host a conference call and webcast at 4:30 p.m. ET on the same day. The webcast can be accessed at https://events.q4inc.com/attendee/164444215 or via the Investor Relations page. U.S. participants can dial 1 833 470 1428 (access code: 638217). International dial-in numbers are available at https://www.netroadshow.com/conferenci...
07-14 11:00
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences, Inc. granted restricted stock units (RSUs) to 66 employees, totaling 135,978 shares, as an inducement for joining the company under its 2022 Inducement Plan. The RSUs will vest over four years, with 25% vesting annually. Castle Biosciences, a diagnostics company improving health through innovative tests, specializes in tests for skin cancers, Barrett’s esophagus, and uveal melanoma, with ongoing R&D in high-need diseases. The ...
06-19 11:00
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Castle Biosciences collaborates with SciBase to develop a diagnostic test predicting AD flares using Electrical Impedance Spectroscopy. The goal is to enable preemptive treatment for up to 24 million U.S. patients. SciBase focuses on EU, UAE, Japan, and South Korea, while Castle targets North America. Financial terms include royalties, mark-ups, and a $5 million milestone payment. The partnership leverages existing portfolios and addresses unmet ...
06-16 20:30
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
Castle Biosciences' CEO Derek Maetzold will participate in a panel discussion at the 2025 BIO International Convention in Boston, focusing on challenges in commercializing innovative diagnostic tests in precision medicine. The session, "Advancing Innovative Risk-Stratification Tests," will take place on June 17 and include leaders from Illumina Ventures and Concert. Castle Biosciences, a diagnostics company offering tests for skin cancers and oth...
06-11 11:00
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
Derek Maetzold, founder and CEO of Castle Biosciences, was awarded the Gold-level Stevie® Lifetime Achievement Award for transformative leadership in healthcare, particularly in molecular diagnostics and precision medicine. The award recognizes his vision, scientific expertise, and commitment to improving patient care. Under his leadership, Castle Biosciences has grown into a industry leader, fundamentally changing clinical care. Judges highlight...
06-04 11:00
Castle Biosciences Announces It Will Present Research Aimed At Enhancing The Clinical Management Of Patients With Cutaneous Melanoma And Uveal Melanoma At The 2025 American Society Of Clinical Oncology Annual Meeting
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous
05-30 04:40
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
Castle Biosciences will present research at the 2025 ASCO meeting showing their DecisionDx-Melanoma test reduces melanoma mortality risk by 32% in a real-world cohort of over 13,500 patients. The test provides more precise risk predictions than AJCC staging. Additionally, a novel 16-protein liquid biopsy for uveal melanoma shows promise in identifying high-risk tumors with 91% sensitivity.
05-29 20:30
Scotiabank Maintains Sector Outperform on Castle Biosciences, Lowers Price Target to $40
Scotiabank analyst Sung Ji Nam maintains Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform and lowers the price target from $44 to $40.
05-21 23:50
